| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 07/31/2002 | EP1227084A1 Drug discharge pump inhibitors |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226817A2 Anti-germ attachment composition |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226264A2 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus |
| 07/31/2002 | EP1226263A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 07/31/2002 | EP1226257A2 Screening and use of agents which block or activate intein splicing utilizing natural or homologous exteins |
| 07/31/2002 | EP1226256A1 Recombinant therapeutic fusion proteins |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226248A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 07/31/2002 | EP1226247A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 07/31/2002 | EP1226246A1 Polypeptides with expanded primary signalling motifs |
| 07/31/2002 | EP1226245A2 Hybrid adaptor receptors |
| 07/31/2002 | EP1226244A2 Polypeptides with non-natural primary signalling motifs |
| 07/31/2002 | EP1226242A1 Human cub-domain-containing protein and gene encoding the same |
| 07/31/2002 | EP1226239A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 07/31/2002 | EP1226235A2 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 07/31/2002 | EP1226176A1 Production of mammary secretion antibodies in farm animals |
| 07/31/2002 | EP1226170A2 Human proteins and polynucleotides encoding the same |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226146A2 Quinoline and naphthyridine carboxylic acid antibacterials |
| 07/31/2002 | EP1226143A2 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226140A1 Novel indole compounds |
| 07/31/2002 | EP1226138A1 Fab i inhibitors |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226115A1 Novel carbamates and ureas |
| 07/31/2002 | EP1226112A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 07/31/2002 | EP1226109A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1226104A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1225923A1 Method of inactivating pathogens |
| 07/31/2002 | EP1225920A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225907A1 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions |
| 07/31/2002 | EP1225905A1 The use of a positively charged carbohydrate polymer for the prevention of infection |
| 07/31/2002 | EP1225904A2 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infection |
| 07/31/2002 | EP1225898A2 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 07/31/2002 | EP1225896A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1225895A1 Fab i inhibitors |
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | EP1225887A2 Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| 07/31/2002 | EP1225874A1 Antiviral compositions |
| 07/31/2002 | EP1049490B1 Method for inhibiting cd95-independent apoptosis in aids |
| 07/31/2002 | EP0980377B1 Anti-viral pyrimidine nucleoside analogues |
| 07/31/2002 | EP0914115A4 Methods of providing neuroprotection |
| 07/31/2002 | EP0799047B1 Viscous liquid conditioning topical germicides |
| 07/31/2002 | EP0760650B1 Antimicrobial oil-in-water emulsions |
| 07/31/2002 | EP0744955B1 Cyclic heptapeptide anti-inflammatory agent |
| 07/31/2002 | EP0735871B1 Pharmaceutical compositions containing ceftriaxone and penems |
| 07/31/2002 | EP0719267B1 Second messenger cell signaling inhibitors |
| 07/31/2002 | EP0708656B1 Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| 07/31/2002 | CN1361825A Novel antifungal agents and fungicides method for the production thereof and their use |
| 07/31/2002 | CN1361824A Porcine circovirus recombinant poxvirus vaccine |
| 07/31/2002 | CN1361793A Expression and export of interferon-alpha proteins as Fc fusion proteins |
| 07/31/2002 | CN1361792A Cyclic peptide derivatives as inhibitors of integrin alpha/beta |
| 07/31/2002 | CN1361791A Process for deacylation of lipodepsipeptides |
| 07/31/2002 | CN1361790A Amine-modified pseudomycin compounds |
| 07/31/2002 | CN1361783A Thiazoloderivatives and pharmaceutical compositions containing them |
| 07/31/2002 | CN1361780A Purine derivatives, preparation method and pharmaceutical compositions containing same |
| 07/31/2002 | CN1361779A New compounds |
| 07/31/2002 | CN1361776A Novel fluorinated imidazoline Benzodioxane, preparation and therapeutic uses thereof |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361765A Inhibitors of aspartyl protease |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361760A Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 07/31/2002 | CN1361694A Glycyrrhizin preparations for transmucosal absorption |
| 07/31/2002 | CN1361106A Corter pseudolaricis acetic acid derivative and its medicinal composite and their antineoplastic and antifungal application |
| 07/31/2002 | CN1360920A Nanometer antiphlogistic Lonicerae and Forsythiae medicine and its prepn |
| 07/31/2002 | CN1360913A Nanometer Xiaojing medicine and its prepn |
| 07/31/2002 | CN1360892A Dry mixed suspension of Meptin and pseudoephe and its prepn |
| 07/31/2002 | CN1360886A Gargle with lysostaphin complex enzyme and its prepn |
| 07/31/2002 | CN1360833A Prepn for earthworm antibacterial peptide |
| 07/31/2002 | CN1088362C Method of administering azithromycin |
| 07/31/2002 | CN1088357C Microgranules of 5-nitro imidazole derivatives |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426412 Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements |
| 07/30/2002 | US6426401 Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction |
| 07/30/2002 | US6426369 Oxethazaine as antimicrobial agent |
| 07/30/2002 | US6426345 Phosphodiesterase inhibitors; antiinflammatory agents |
| 07/30/2002 | US6426334 Administering nucleotide sequence |
| 07/30/2002 | US6426088 Sustained release; in situ insertion |
| 07/30/2002 | US6426071 Administering protein c |
| 07/30/2002 | US6426068 Prevent cell or organ degradation; plant extracts |
| 07/30/2002 | US6426066 Use of physiologically balanced, ionized, acidic solution in wound healing |
| 07/30/2002 | CA2369405A1 Har a polypeptides and nucleic acids, and related methods and uses thereof |
| 07/30/2002 | CA2268433C Improved interferon polymer conjugates |
| 07/30/2002 | CA2226293C Hcv ns3 protein fragments having helicase activity and improved solubility |
| 07/30/2002 | CA2084673C 16 kda surface protein of p.falciparum |
| 07/30/2002 | CA2079777C Oligonucleotide analogs |
| 07/30/2002 | CA2056619C Method of inactivation of viral and bacterial blood contaminants |
| 07/25/2002 | WO2002057454A2 Receptors and membrane-associated proteins |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057425A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057408A2 Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same |
| 07/25/2002 | WO2002057327A1 Method of preparing poly(vinyl pivalate) |
| 07/25/2002 | WO2002057315A2 Streptococcal streptolysin s vaccines |
| 07/25/2002 | WO2002057314A2 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |